Status:
COMPLETED
Comparison of Biphasic Insulin Aspart 70/30 Versus Insulin Glargine in Subjects With Type 2 Diabetes
Lead Sponsor:
Novo Nordisk A/S
Conditions:
Diabetes
Diabetes Mellitus, Type 2
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
This trial is conducted in the United States of America (USA). The purpose of this study is to test whether Biphasic Insulin Aspart 70/30 twice a day with Metformin improves glycemic control vs. once ...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Type 2 Diabetes
Exclusion
Key Trial Info
Start Date :
January 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2006
Estimated Enrollment :
293 Patients enrolled
Trial Details
Trial ID
NCT00097877
Start Date
January 1 2005
End Date
November 1 2006
Last Update
January 11 2017
Active Locations (73)
Enter a location and click search to find clinical trials sorted by distance.
1
Novo Nordisk Investigational Site
Birmingham, Alabama, United States, 35235
2
Novo Nordisk Investigational Site
Tuscaloosa, Alabama, United States, 35406
3
Novo Nordisk Investigational Site
Vestavia Hills, Alabama, United States, 35209
4
Novo Nordisk Investigational Site
Searcy, Arkansas, United States, 72143